Lung Cancer Flashcards
Alecensa
alectinib
ALK inhibitor
Xalkori
crizotinib
ALK inhibitor
ROS1 inhibitor
Zykadia
ceritinib
ALK inhibitor
ROS1 inhibitor
Alunbrig
brigatinib
ALK inhibitor
Lorbrena
lorlatinib
ALK inhibitor
ROS1 inhibitor
Rozlytrek
entrectinib
ROS1 inhibitor
NTRK inhibitor- pan tumor indication
Lumakras
Sotorasib
KRAS G12C inhibitor
Tarceva
Erlotinib
EGFR inhibitor
Gilotrif
Afatinib
EGFR inhibitor
Iressa
Gefitinib
EGFR inhibitor
Tagrisso
Osimertinib
EGFR inhibitor
Effective against T790M mutation
Vizimpro
Dacomitinib
EGFR inhibitor
Drugs for Exon 20 Insertion Mutation (2)
Rybrevant (Amivantamab) IV
BISPECIFIC EGFR/MET target ADCC
Exkivity (Mobocertinib) PO
Portrazza
Necitumumab (IV)
EGFR inhibitor for squamous cell NSCLC
Tafinlar + Mekinist
Tafinlar (Dabrafinib)- BRAF inhibitor
Mekinist (Trametinib) MEK inhibitor
Retevmo
Selpercatinib
Indications
NSLC - RET fusion
MTC - RET mutation
Thyroid Cancer - RET fusion
Solid tumors with RET fusion
< 50 kg 120 MG twice daily
> 50 kg 160 MG twice daily
HHH coughing up a cutie
TLS
Impaired wound healing (VEGF)
Gavreto
Pralsetinib
Same indications as Retevmo EXCEPT no pan-tumor indication
400 MG once daily on an empty stomach
No QT warning
Tabrecta
Capmatinib
MET inhibitor
Tepmetko
Tepotinib
MET inhibitor
MET exon 14 skipping alterations
